A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults
Stéphane Pillet, Éric Aubin, Sonia Trépanier, Diane Bussière, Michèle Dargis, Jean-François Poulin, Bader Yassine-Diab, Brian J Ward, Nathalie Landry, Stéphane Pillet, Éric Aubin, Sonia Trépanier, Diane Bussière, Michèle Dargis, Jean-François Poulin, Bader Yassine-Diab, Brian J Ward, Nathalie Landry
Abstract
Recent issues regarding efficacy of influenza vaccines have re-emphasized the need of new approaches to face this major public health issue. In a phase 1-2 clinical trial, healthy adults received one intramuscular dose of a seasonal influenza plant-based quadrivalent virus-like particle (QVLP) vaccine or placebo. The hemagglutination inhibition (HI) titers met all the European licensure criteria for the type A influenza strains at the 3μg/strain dose and for all four strains at the higher dosages 21days after immunization. High HI titers were maintained for most of the strains 6months after vaccination. QVLP vaccine induced a substantial and sustained increase of hemagglutinin-specific polyfunctional CD4 T cells, mainly transitional memory and TEMRA effector IFN-γ(+) CD4 T cells. A T cells cross-reactive response was also observed against A/Hong-Kong/1/1968 H3N2 and B/Massachusetts/2/2012. Plant-based QVLP offers an attractive alternative manufacturing method for producing effective and HA-strain matching seasonal influenza vaccines.
Keywords: Cell-mediated immunity; Cross-reactive response; Nicotiana benthamiana; Plant-derived quadrivalent influenza vaccine; Safety and immunogenicity; Virus-like particles.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed